Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or, Peter Calabresi, Douglas Arnlod, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith

Research output: Contribution to journalArticle

Abstract

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalAnnals of Neurology
Volume63
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Gadolinium
B-Lymphocytes
Safety
Recurrence
Infection
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Bar-Or, A., Calabresi, P., Arnlod, D., Markowitz, C., Shafer, S., Kasper, L. H., ... Smith, C. H. (2008). Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Annals of Neurology, 63(3), 395-400. https://doi.org/10.1002/ana.21363

Rituximab in relapsing-remitting multiple sclerosis : A 72-week, open-label, phase I trial. / Bar-Or, Amit; Calabresi, Peter; Arnlod, Douglas; Markowitz, Clyde; Shafer, Stuart; Kasper, Lloyd H.; Waubant, Emmanuelle; Gazda, Suzanne; Fox, Robert J.; Panzara, Michael; Sarkar, Neena; Agarwal, Sunil; Smith, Craig H.

In: Annals of Neurology, Vol. 63, No. 3, 03.2008, p. 395-400.

Research output: Contribution to journalArticle

Bar-Or, A, Calabresi, P, Arnlod, D, Markowitz, C, Shafer, S, Kasper, LH, Waubant, E, Gazda, S, Fox, RJ, Panzara, M, Sarkar, N, Agarwal, S & Smith, CH 2008, 'Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial', Annals of Neurology, vol. 63, no. 3, pp. 395-400. https://doi.org/10.1002/ana.21363
Bar-Or, Amit ; Calabresi, Peter ; Arnlod, Douglas ; Markowitz, Clyde ; Shafer, Stuart ; Kasper, Lloyd H. ; Waubant, Emmanuelle ; Gazda, Suzanne ; Fox, Robert J. ; Panzara, Michael ; Sarkar, Neena ; Agarwal, Sunil ; Smith, Craig H. / Rituximab in relapsing-remitting multiple sclerosis : A 72-week, open-label, phase I trial. In: Annals of Neurology. 2008 ; Vol. 63, No. 3. pp. 395-400.
@article{5920604538884c71ac8198b85617d1b3,
title = "Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial",
abstract = "We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.",
author = "Amit Bar-Or and Peter Calabresi and Douglas Arnlod and Clyde Markowitz and Stuart Shafer and Kasper, {Lloyd H.} and Emmanuelle Waubant and Suzanne Gazda and Fox, {Robert J.} and Michael Panzara and Neena Sarkar and Sunil Agarwal and Smith, {Craig H.}",
year = "2008",
month = "3",
doi = "10.1002/ana.21363",
language = "English (US)",
volume = "63",
pages = "395--400",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Rituximab in relapsing-remitting multiple sclerosis

T2 - A 72-week, open-label, phase I trial

AU - Bar-Or, Amit

AU - Calabresi, Peter

AU - Arnlod, Douglas

AU - Markowitz, Clyde

AU - Shafer, Stuart

AU - Kasper, Lloyd H.

AU - Waubant, Emmanuelle

AU - Gazda, Suzanne

AU - Fox, Robert J.

AU - Panzara, Michael

AU - Sarkar, Neena

AU - Agarwal, Sunil

AU - Smith, Craig H.

PY - 2008/3

Y1 - 2008/3

N2 - We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

AB - We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

UR - http://www.scopus.com/inward/record.url?scp=41849116363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849116363&partnerID=8YFLogxK

U2 - 10.1002/ana.21363

DO - 10.1002/ana.21363

M3 - Article

C2 - 18383069

AN - SCOPUS:41849116363

VL - 63

SP - 395

EP - 400

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -